Table 2.
Table showing localisation of recurrence, pathologic and treatment characteristics and outcome of patients with local and metastatic recurrence
| Localisation of recurrence | Histology (Mixed or pure SmCC) | Treatment | Response | Survival (months) | Death |
| Rectum | mixed | Surgery + CT (3EP) + RT | Progressive | 7.1 | yes |
| Neo-bladder | Mixed | CT (6MVAC) | PR < 50% | 10 | yes |
| RP | Pure | CT (4EP) | Stable | 5.5 | yes |
| RP | Mixed | RT (Y 45 Gy) + chemotherapy (4G) | Stable | 7.7 | yes |
| RP | Mixed | CT (4GC) + RT (Y 45 Gy) | CR | 28.8 | yes |
| CNS | Pure | CT (1 EP + 1 MTX intrathecal) | - | 0.4 | yes |
| CNS | Pure | RT (30 Gy) | Progressive | 3.7 | yes |
| Liver and RP | Mixed | CT (1GC) | Progressive | 0.7 | yes |
| Liver and RP | Mixed | CT (4G) | Progressive | 3.1 | yes |
| Liver and Bone | Pure | CT (6EP) | PR > 50% | 20.3 | no |
| Lung and RP | Mixed | CT (6EP) | PR > 50% | 14.7 | no |
| Lung | Mixed | CT (6EP in first line and 6GC in second line) | PR > 50% (in first line) | 26.3 | yes |
SmCC = small cell carcinoma; CNS = central nervous system; RP = retroperitoneal; EP = etoposide and cisplatin; G = gemcitabine; GC = gemcitabine plus cisplatin; MVAC = methotrexate, vinblastine, doxorubicin and cisplatin; MTX = methotrexate; CT = chemotherapy; RT = radiotherapy; Y = Y field radiotherapy; PR = partial response; CR = complete response, NA = not applicable